Chicago-based Exicure Inc., an early-phase biotech firm, is working on developing nucleic acid therapies using ribonucleic acid to target validated goals. Their preclinical drug candidate features SCN9A, currently in preclinical trials intended for the treatment of chronic pain. The company also focuses on developing immuno-oncology therapeutics reliant on their proprietary SNA technology. Founded in 2011, Exicure Inc. continues to evolve and grow within the biotechnology industry with their promising developments in nucleic acid therapy.